��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title A New Validated Patient-Completed Neuropathic Pain Screening Tool for Use in the Primary Care Setting

Topic Headache and Pain

Presentation(s) (-)

Poster/Presentation
Number 160

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Philippe Beauchemin, MD	Dr. Beauchemin has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Dr. Beauchemin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche Canada. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Canada. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pendopharm. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Beauchemin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Ali M. Al-Salahat, MBBS (Creighton University - Neurology Program)	Dr. Al-Salahat has nothing to disclose.
	No disclosure on file
	No disclosure on file
Carissa C. Dioquino	No disclosure on file
	No disclosure on file
Raed Alroughani, MD, FAAN	Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, AstraZeneca, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca, Biogen, Novartis, Merck, Roche, Sanofi.